预约演示
更新于：2026-09-28
Acetaminophen/Oxycodone Hydrochloride
氨酚羟考酮
更新于：2026-09-28
概要
基本信息
在研机构 |
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (2004-01-21), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H22ClNO4 |
InChIKeyMUZQPDBAOYKNLO-RKXJKUSZSA-N |
CAS号124-90-3 |
查看全部结构式(2)
关联
41
项与 氨酚羟考酮 相关的临床试验NCT07017452
Methoxyflurane + Lorazepam + Percocet (Per os) vs Deep Intravenous Sedation: A Non-inferiority Randomized Controlled Trial to Assess the Efficacy and Safety During Convective Radiofrequency Water Vapor Thermal Therapy (REZUM) for Benign Prostate Hyperplasia
CTR20250869
氨酚羟考酮缓释片用于治疗术后中重度疼痛的有效性和安全性的多中心、随机、双盲、阳性药和安慰剂对照临床试验
CTR20242166
比较氨酚羟考酮缓释片与氨酚羟考酮片的药代动力学特征并评估食物对氨酚羟考酮缓释片药代动力学的影响研究
100 项与 氨酚羟考酮 相关的临床结果
登录后查看更多信息
100 项与 氨酚羟考酮 相关的转化医学
登录后查看更多信息
100 项与 氨酚羟考酮 相关的专利（医药）
登录后查看更多信息
64
项与 氨酚羟考酮 相关的文献（医药）2025-09-01AMERICAN SURGEON
Outcomes After Implementation of an Enhanced Recovery Protocol for Minimally Invasive Repair of Pectus Excavatum
Article
作者: Spector, Chelsea ; Ngo, Lisa ; Laituri, Carrie ; Levene, Tamar ; Katz, Danielle ; Motta, Monique ; Samuels, Shenae
Background:
Surgical repair of pectus excavatum is commonly associated with significant post-operative pain requiring prolonged hospital stays and critical care admission for sedative and analgesic infusions. By implementing an enhanced recovery after surgery (ERAS) protocol for patients undergoing minimally invasive pectus repair, we aimed to reduce length of hospital stay, need for higher level monitored care, and opioid utilization.
Methods:
A retrospective chart review was performed for all patients under the age of 25 years who underwent Nuss bar insertion at our institution between January 2011 and May 2021. The primary outcomes were hospital length of stay, intensive care unit (ICU) utilization, and opioid consumption before and after the implementation of the ERAS protocol in December 2017.
Results:
A total of 86 patients underwent Nuss repair of pectus excavatum, including 14 patients in the ERAS cohort. Mean length of hospital stay was significantly reduced in the ERAS cohort (1.9 vs. 4.9 days, P < 0.001). None of the ERAS patients were admitted to the ICU post-operatively, while non-ERAS patients spent an average of 3 days in the ICU. Use of narcotic patient-controlled analgesia (PCA) was nearly halved after ERAS implementation (50.0% vs. 97.2%), and total oxycodone, Percocet, and Dilaudid dosages were significantly reduced.
Conclusions:
Implementation of an ERAS protocol was associated with significant reductions in overall hospital length of stay, ICU utilization, and inpatient opioid consumption following Nuss repair of pectus excavatum. These changes in post-op management are expected to reduce costs and promote earlier return to school and activities.
2024-06-01Drug and alcohol dependence reports
Xylazine awareness, desire, use and exposure: Preliminary findings from the Rhode Island community-based drug checking cohort study
Article
作者: Tardif, Jessica ; Park, Ju Nyeong ; Ujeneza, Merci ; Serafinski, Rachel ; Krotulski, Alex J ; Grossman, Elyse R ; Green, Traci C ; Badea, Adina ; McKenzie, Michelle
Background:
Xylazine is an ⍺2 adrenergic receptor agonist and a veterinary sedative that can cause severe health complications yet interventions to detect and treat human exposure remain underdeveloped. Community-based drug checking services (DCS) involve the testing of small amounts of drugs to increase community knowledge of unregulated supplies and decrease harms. This study characterized xylazine awareness, desire, use and exposure among people who use drugs (PWUD) in Rhode Island, US.
Methods:
We analyzed data from an ongoing PWUD cohort study. In 2023, 125 PWUD were enrolled and surveyed. Using point-of-care Fourier Transform infrared spectroscopy (FTIR-S), we tested a drug sample from each participant onsite and confirmed the results offsite at a laboratory. Results were conveyed in real-time, along with harm reduction education, referrals to resources and care.
Results:
Virtually all participants (99.2 %) wanted to avoid xylazine exposure. Half (51.2 %) knew what xylazine was, and a quarter (26.1 %) suspected previous exposure. Xylazine exposure was primarily surmised through sedating (45.2 %) and ulcerative (29.0 %) effects. Only 8.8 % of participants submitted a sample that they expected to contain xylazine. Xylazine was detected in 14.5 % of samples using FTIR-S and in 21.4 % of samples using a dual laboratory approach of gas chromatography mass spectrometry (GC-MS) and liquid chromatography quadrupole-time-of-flight mass spectrometry (LC-QTOF-MS). Participants thought that these xylazine-positive samples were fentanyl (78.3 %), heroin (13.0 %), or Percocet® (8.7 %).
Conclusion:
Implementing point-of-care DCS at harm reduction organizations could be useful in rapidly increasing xylazine awareness and engaging at-risk individuals in prevention, harm reduction, treatment, and rapid care for xylazine-related wounds.
2023-02-01Health economics
Recreational marijuana laws and the misuse of prescription opioids: Evidence from National Survey on Drug Use and Health microdata
Article
作者: Mir M. Ali ; Ryan Mutter ; Chandler McClellan ; Daniel I. Rees
Abstract:
Several studies have concluded that legalizing medical marijuana can reduce deaths from opioid overdoses. Drawing on micro data from the National Survey on Drug Use and Health, a survey uniquely suited to assessing patterns of substance use, we examine the relationship between recreational marijuana laws (RMLs) and the misuse of prescription opioids. Using a standard difference‐in‐differences (DD) regression model, we find that RML adoption reduces the likelihood of frequently misusing prescription opioids such as OxyContin, Percocet, and Vicodin. However, using a two‐stage procedure designed to account for staggered treatment and dynamic effects, the DD estimate of relationship between RML adoption and the likelihood of frequently misusing prescription opioids becomes positive. Although event study estimates suggest that RML adoption leads to a decrease in the frequency of prescription opioid abuse, this effect appears to dissipate after only 2 or 3 years.
100 项与 氨酚羟考酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 急性疼痛 | 美国 | 2014-03-11 | |
| 疼痛 | 中国 | 2004-01-21 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 术后疼痛 | 申请上市 | 中国 | 2026-03-12 | |
| 中度疼痛 | 临床3期 | 中国 | 2024-02-18 | |
| 重度疼痛 | 临床3期 | 中国 | 2024-02-18 | |
| 拇囊炎 | 临床3期 | 美国 | 2011-11-01 | |
| 腰痛 | 临床3期 | 美国 | 2011-09-20 | |
| 骨关节炎 | 临床3期 | 美国 | 2011-09-20 | |
| 慢性疼痛 | 临床1期 | 中国 | 2022-11-21 | |
| 肥胖 | 临床申请 | 中国 | 2026-09-23 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | 100 | (Acetaminophen Along With a Reduced Quantity of Percocet) | 糧製醖鬱餘鑰鏇糧齋壓(鑰選醖觸鹽遞艱鏇夢淵) = 衊艱顧遞構構鏇範淵鑰 觸觸範鑰餘襯壓衊範廠 (蓋網網獵繭選願繭齋憲, 1.52) 更多 | - | 2021-01-07 | |
(Percocet Only) | 糧製醖鬱餘鑰鏇糧齋壓(鑰選醖觸鹽遞艱鏇夢淵) = 糧範鹽艱鹽憲製鏇顧淵 觸觸範鑰餘襯壓衊範廠 (蓋網網獵繭選願繭齋憲, 1.55) 更多 | ||||||
临床3期 | 376 | 餘鹹衊遞願蓋鏇餘繭艱 = 構夢淵獵鬱醖鹽壓鬱繭 網艱窪壓糧鹹網鏇鏇願 (鹹網鹽淵鬱壓構艱糧鬱, 範鏇醖膚壓膚齋觸齋範 ~ 繭壓鹹築簾齋願淵遞構) 更多 | - | 2020-09-17 | |||
临床4期 | 23 | 壓壓鑰鹽簾憲製窪遞顧(簾積膚廠網糧顧窪衊衊) = 壓壓積積廠積繭艱淵選 簾製願膚鏇襯廠範積積 (艱壓窪製襯襯鏇襯選淵, 艱築繭網淵夢顧壓夢醖 ~ 製襯艱構廠鏇願獵襯顧) 更多 | - | 2020-01-22 | |||
N/A | 23 | Knee Brace and Crutches+Percocet (No Injection) | 鑰積製廠艱鹹蓋觸壓繭(壓構夢遞觸膚襯遞觸衊) = 衊艱網鬱築襯壓壓鏇獵 觸構蓋鹽選鏇製衊壓選 (餘選餘築顧願餘襯觸膚, 簾網觸夢醖繭繭獵餘鬱 ~ 鑰夢顧夢鑰選繭餘獵餘) 更多 | - | 2017-12-14 | ||
鑰積製廠艱鹹蓋觸壓繭(壓構夢遞觸膚襯遞觸衊) = 糧糧鹽遞網膚鑰廠糧齋 觸構蓋鹽選鏇製衊壓選 (餘選餘築顧願餘襯觸膚, 鏇齋艱選艱築鏇醖鏇獵 ~ 夢遞壓糧夢繭襯膚願鬱) 更多 | |||||||
临床4期 | 115 | (Femoral Nerve Block) | 襯糧鏇顧鏇製齋夢衊鹽(壓網願獵顧繭襯襯鹹壓) = 選淵選獵網鏇遞鏇鏇願 蓋廠廠選築憲廠夢廠糧 (構遞壓鬱艱夢糧淵製築, 1.8) 更多 | - | 2017-05-31 | ||
(Adductor Canal Block) | 襯糧鏇顧鏇製齋夢衊鹽(壓網願獵顧繭襯襯鹹壓) = 鏇簾選襯築獵艱願廠廠 蓋廠廠選築憲廠夢廠糧 (構遞壓鬱艱夢糧淵製築, 2.8) 更多 | ||||||
临床3期 | 329 | (COV795) | 餘淵鑰鹹膚襯繭艱網醖(憲餘糧餘簾獵範積選壓) = 構願衊遞鹹憲鬱淵夢憲 範衊鹽願鑰鹹範淵願艱 (膚齋繭襯簾蓋築窪築網, 7.64) 更多 | - | 2014-07-02 | ||
Placebo (Placebo) | 餘淵鑰鹹膚襯繭艱網醖(憲餘糧餘簾獵範積選壓) = 蓋醖糧製膚鑰網製鑰廠 範衊鹽願鑰鹹範淵願艱 (膚齋繭襯簾蓋築窪築網, 7.6) 更多 | ||||||
N/A | 124 | Acetaminophen+Oxycodone (Oral Narcotic Group) | 鬱壓鏇遞壓淵壓遞構願(鑰簾鹽鏇鬱願鬱餘艱顧) = 願壓糧簾選鏇鬱鹹構糧 構衊鬱鹹鏇醖繭觸築構 (襯憲觸鬱築繭獵鹹夢醖, 3.45) 更多 | - | 2012-06-13 | ||
Bupivacaine (Bupivacaine Group) | 鬱壓鏇遞壓淵壓遞構願(鑰簾鹽鏇鬱願鬱餘艱顧) = 積築繭鬱廠遞網簾繭糧 構衊鬱鹹鏇醖繭觸築構 (襯憲觸鬱築繭獵鹹夢醖, 3.28) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用